natgillin/translations-raw huggingface dataset:
Add 25 kg of starch to the hopper after each cycle. 
Dodati 25 kg škroba u uljevni lijevak poslije svakog ciklusa.
variable and constant light chain sequences: 
(1) sekvenci varijabilnog i konstantnog lakog lanca:
wherein is a hydrogen atom, a halogen atom or a lower alkyl group optionally having substituent(s); 
R' je atom vodika, atom halogena ili alkilna skupina koja ima broj ugljika od 1 do 6 opcijski sa supstituentima;
The container of claim 1, wherein the first retention members are arranged around the opening to have only a single plane of rotational symmetry. 
Posuda (100) prema bilo kojem prethodnom patentnom zahtjevu, pri čemu su zadržmi elementi (140) raspoređeni oko otvora (110) da imaju samo jednu ravan rotacijske simetrije.
The compound of claim 25 wherein the therapeutic agent is an anticonvulsant or' a contraceptive agent. 
Spoj u skladu sa zahtjevom 25, naznačen time, da terapeutsko sredstvo je antikonvulzivno ili kontracepcijsko sredstvo.
an HDAC inhibitor, wherein the HDAC inhibitor is a compound of the following formula: and 
(a) HDAC inhibitor, pri čemu je HDAC inhibitor spoj sa sljedećom formulom: i
The bacterial species for use according to any preceding embodiment which upregulates expression of at least one gene selected from Ly6g6c and Ly6g6e in the ascending colon. The bacterial species for use according to any preceding embodiment which regulates the expression of at least one gene selected from Tlr5, Tlrl, Vnn1, Defb37, Pla2g, Mud 6, Itln, Sprria, Cldn4, Pmp22, Crb3, Magi3, Marveld3, Mpp7, Defcr20, Pcgf2, Ltbp4, Igsf8 and Tcfe2a. 
(vii) pozitivno regulira ekspresiju najmanje jednog gena izabranog od Ly6g6c i Ly6g6e u uzlaznom kolonu; ili (vili) regulira ekspresiju najmanje jednog gena koji je izabran od Tlr5, TiR1, Vnn1, Defb37, Pla2g, Muc16, ltln, Sprrla, Cldn4, Pmp22, Crb3, Magi3, Marveld3, Mpp7, Defcr20, Pcgf2, Ltop4, Igsf8 i Tcfe2a.
A process according to claim 1, characterised in that a filling medium is used which is immiscible with and/or is not dissolved by a cooling lubricant used for mechanical machining, and a filling medium is preferably used which is not soluble in water. 
2. Postupak prema zahtjevu 1, naznačen time, da se upotrebljava punilo koje se ne miješa i/ili koje se ne otapa u sredstvu za hlađenje upotrijebljenom za mehaničku strojnu obradu, i upotrijebljeno punilo ponajprije nije topivo u vodi.
m stands for a relative intensity of less than 75% to 55 %; and w stands for a relative intensity of less than 55%. 
m znači relativni intenzitet manji od 75% do 55 %; i w znači relativni intenzitet manji od 55%.
The use of claim 4, wherein the cancers or tumors are induced by an epidermal growth factor receptor (EGFR) tyrosine kinase or a mutant thereof. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što su rak ili tumori inducirani tirozinskom kinazom vezanom uz receptor čimbenika rasta epiderme (EGFR) ili njezinim mutantom.
separating the elemental metal from the ash. 
odvajanja elementarnog metala od pepela.
Examples of excipients used for the preparation of solid pharmaceutical compositions include, for example, lactose, sucrose, starch, talc, cellulose, dextrin, kaolin, calcium carbonate and the like. 
Primjeri pomoćnih tvari koje se upotrebljava u pripravi čvrstih farmaceutskih pripravaka uključuju, primjerice, laktozu, saharozu, škrob, talk, celulozu, dekstrin, kaolin, kalcijev karbonat i slično.
in which R3 is as defined above, and is hydrogen, (C1-C4)-alkyl, or the two T6 radicals together form a —C(CH3)2—C(CH3)2— bridge to give a compound of the formula (I-1), 
" ić? iš, gdje R je kako je gore definirano i T* je vodik, (Cy-Cx)-alkil, ili dva T" radikala zajedno tvore -C(CH>),-C(CH3),-most da se dobije spoj s formulom (I-1), ili
As indicated in FIG. 4, a typical width of mist might be 5 to 15 centimeters wide at the harvested crop. 
Kako je prikazano na slici 4, tipična širina raspršene magle može biti 5 do 15 cm na ubranom usjevu.
The immunogenic composition of claim 1 or 2 wherein the at least one additional bacterial saccharide conjugate(s) comprises a N. meningitidis capsular saccharide derived from a strain selected from the group consisting of serogroups A, B, C, W135 and Y. 
Imunogeni pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije N. meningitidis kojeg se dobiva iz soja kojeg se bira iz skupine koju čine seroskupine A, B, C, W135i Y.
A method to lyse a fat cell, the method comprising administering to said cell a precipitation-stable aqueous pharmaceutical composition consisting essentially of 0.4% w/v to 1% w/v of a salt of deoxycholic acid and a pharmaceutically acceptable excipient, and wherein said composition is maintained at a pH from 8.2 to 8.5. 
Taložno stabilan vodeni farmaceutski pripravak, naznačen time što se uglavnom sastoji od 0,4% tež./vol. Do 1% tež./vol. soli deoksikolne kiseline i farmaceutski prihvatljive pomoćne tvari, te što se pH navedenog pripravka održava na 8,2 do 8,5.
The installation process will be described in further detail in the following with reference to Figures 2a-2c that show a first embodiment of a beverage dispensing assembly according to the invention. 
Postupak postavljanja će se sada opisati u daljnjim pojedinostima pomoću slika 2a-2c, koje prikazuju prvu izvedbu sklopa za točenje pića prema izumu. HR P20070257 T3
The expanded, cellular material according to claim 1 or claim 2, wherein the physical blowing agent is either a hydrocarbon, fluorocarbon, argon, nitrogen, CO2, or a mixture thereof. 
Ekspandirani pjenasti materijal prema patentnom zahtjevu 1, naznačen time, da je fizikalni agens za upuhivanje ili ugljikovodik, fluorugljik, argon, dušik, CO2, ili njihova mješavina.
or a salt thereof; and the compound of Formula IIb is represented by Formula IIc 
Formula fo ili njegovom soli te je spoj Formule IIb predstavljen Formulom Ile:
2 depicts a general approach to the preparation of rapamycin carbohydrate derivatives of the present invention. 
Slika2 prikazuje opći pristup pripremi ugljikohidratnih derivata rapamicina ovog izuma.
N, N -Dimethylacetamide (DMAc) (525 mL) was added in one portion at room temperature to dissolve the solids. 
N,N-dimetilacetamid (DMAc) (525 mL) je dodan u jednom obroku, na sobnoj temperaturi, da se otope krutine.
The compound according to claim 1 or 2, wherein R1 is heteroaryl substituted with C1-C3 alkyl. 
Spoj ili sol u skladu s patentnim zahtjevom 1, naznačen time što je R1 heteroaril, supstituiran s C1-C3 alkilom.
The method of claim 16, wherein the other second active agent is a therapeutic antibody that specifically binds to a cancer antigen, hematopoietic growth factor, cytokine, anti-cancer agent, antibiotic, cox-2 inhibitor, immunomodulatory agent, immunosuppressive agent, corticosteroid or a pharmacologically active mutant or derivative thereof. 
Spoj za uporabu u skladu s patentnim zahtjevom 24, naznačen time što je sljedeće drugo aktivno sredstvo terapeutsko antitijelo koje se specifično veže na antigen raka, hematopoetski faktor rasta, citokin, sredstvo protiv raka, antibiotik, inhibitor cox-2, imunomodulacijsko sredstvo, imunosupresivno sredstvo, kortikosteroid ili njegov farmakološki aktivni mutant ili derivat.
Compound according to any one of the preceding claims for use as a medicament. Compound according to any one of the preceding claims for use as a medicament in the treatment of inflammation-associated pain, preferably arthritis, skin inflammation, inflammatory back pain, headache (including neurogenic migraine), inflammatory lesions of the central and peripheral nervous system (neuropathic pain), cancer pain, disorders of the immune system (HIV/AIDS, multiple sclerosis), traumatic pain, postoperative pain, inflamed joints, dental surgery, visceral pain, bone pain, burn injury and/or eye lesions. 
Spoj namijenjen upotrebi kao medikament u skladu s patentnim zahtjevom 7, naznačen time što se bol povezanu s upalom bira iz skupine koju čine artritis, upala kože, upalna bol u leđima, glavobolja, primjerice neurogena migrena, upalne lezije u središnjem i perifernom živčanom sustavu, primjerice neuropatska bol, bol uzrokovana rakom, poremećaji imunosnog sustava, primjerice HIV/AIDS ili multipla skleroza, traumatska bol, postoperativna bol, upaljeni zglobovi, kirurški zahvat na zubalu, visceralna bol, kostobolja, opeklinska ozljeda i lezije oka.
1 shows a drink dispenser 1 according to the present invention provided with a chamber, such as a chill chamber 2, for accommodating a container 3 with a carbonated drink therein, such as, for example, beer. 
1 prikazuje djelitelj pića 1 u skladu s predmetnim izumom koji ima komoru, kao što je hladna komora 2, u koju se smješta spremnik 3, koji u sebi sadrži karbonizirano piće, kao što je, na primjer, pivo.
The method of claim 7, wherein wear resistant material within the cavity is primarily particles less than 1mm in size. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da materijal otporan na habanje unutar šupljine prvenstveno tvore čestice manje od 1 mm.
Moreover, the Polish patent application P.346517 discloses a method for the preparation of risedronic acid by reacting 3-pyridyl acetic acid hydrochloride with phosphorous acid and phosphorus trichloride in chlorobenzene or fluorobenzene. 
U poljskom patentu PL 194770 B (EP 1 243 592 B1) objavljen je postupak za pripravu risedronske kiseline stavljanjem u rcakciju hidroklorida 3-piridil octene kiseline sa fosfitnom kiselinom i fosfor-trikloridom u klorbenzenu ili fluorobenzenu.
The process of claim 2, further comprising: 
Proces iz patentnog zahtjeva 2, koji dalje sadrži:
In a further aspect therefore there is provided a method of treating stroke (particularly ischemic stroke), brain injury, spinal cord injury, fronto-temporal dementias (tauopathies), peripheral neuropathy, Parkinson's disease, Huntington's disease, multiple sclerosis and in particular Alzheimer's disease in a human patient which method comprises the intravenous administration of a therapeutically effective amount of an anti-NOGO antibody of the invention. 
Upotreba protutijela protiv Nogo-A, ili njegovog funkcionalnog fragmenta ili analoga, u skladu s bilo kojim od patentnih zahtjeva 1 do 8, u pripravi medikamenta za liječenje inzulta, traumatske ozljede mozga, ozljede kralježničke moždine, Alzheimerove bolesti, fronto-temporalnih demencija (tauopatija), periferne neuropatije, Parkinsonove bolesti, Huntingtonove bolesti ili multiple skleroze kod čovjeka. .
A kit as defined in claim 13 wherein the second member of a binding pair is avidin, streptavidin or a functionally equivalent variant thereof. 
drugi član vežućeg para, konjugiran s fluorescentnim, luminescentnim ili enzimskim biljegom, gdje se vežući par bira iz skupine koju čine:
The compound according to claim 12, wherein the compound is 3,4- dihydroxy-3′,4′-dimethylbiphenyl-2,6-dicarbonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, daje spoj 3,4-dihidroksi-4'-metilbifenil-2,6-dikarbonitril.
The rate of inhibition by a2-antiplasmin can also be at least about 10-fold, 20-fold, 30-fold, or 40-fold faster than the rate of inhibition of mini-plasmin. 
Polipeptid prema zahtjevu 9, naznačen time da je stupanj inhibicije najmanje oko 10 puta, 20 puta, 30 puta ili 40 puta brži nego stupanj inhibicije mini-plazmina.
contacting the composition with a ligand capable of binding to a prion protein, and 
kontakt pripravka s ligandom sposobnim za vezanje za prion protein, i
Injection moldable pellets of at least essentially fully crystallized, food grade polyethylene terephthalate (PET), said polyethylene terephthalate containing silicon bonded and integrated into its molecular structure. 
Proces za pripravu amorfnog polietilen tereftalata, PET, koji sadrži silikon u obliku vezanom i integriranom u molekulsku strukturu PET-a, naznačen time da se:
The method of the first or second embodiment may additionally comprise the step of: 
(32) Datum podnošenja prve prijave: 22.11.2004.
or a N-oxide or a pharmaceutically acceptable salt thereof. 
ili N-oksid, ili njegova farmaceutski prihvatljiva sol ili solvat.
a monoclonal antibody of any one of claims 1-6 or a fragment thereof, capable of specifically binding in vitro to a repeating conformational epitope of a protofibril form of B-amyloid peptide while showing minimal affinity to low molecular weight forms of B-amyloid peptide; and, 
monoklonsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-6, ili njegov fragment, koje se može specifično vezati in vitro na ponavljani konformacijski epitop protofibrilnog oblika B-amiloidnog peptida, dok pokazuje minimalni afinitet na niskomolekulske oblike B-amiloidnog peptida; i,
The use of one of claims 1 through 6, wherein said avermectin compound is integrated into medicated tape, topical dressing, or dermal patch. 
Uporaba prema jednom od zahtjeva 1 do 6, naznačena time da je navedeni spoj avermektina integriran u medicinsku traku, topikalni zavoj ili kožni flaster.
Possible therapeutical applications for said antagonists are inflammatory, allergic and autoimmune disorders, such as asthma and chronic bronchitis (also induced by irritants), allergic, vasomotor and viral rhinitis, obstructive pulmonary disease (COPD), rheumatoid arthritis, chronic inflammatory diseases of the bowel (Crohn's disease and ulcerative colitis), glomerulonephritis, psoriasis, rash, acute and chronic cystitis; degenerative disorders characterized by fibrosis, such as hepatic cirrhosis, glomerulopathies and pulmonary fibrosis, arteriosclerosis; thanks to their analgesic activity, in the treatment of both acute and chronic pain, for example in burns, cephalea, insects bites, chronic pain in cancer patients; in disorders of the cardiovascular apparatus such as septic, allergic and post-traumatic shocks, and hepatic cirrhosis by hepatorenal syndrome; as anticancer and antiangiogenetics; in the treatment of hypotension and of alopecia. 
Moguće terapijske primjene rečenih antagonista su upalni, alergijski i autoimuni poremećaji, kao što je astma i kronični bronhitis (također induciran iritantima), alergijski, vazomotorni i virusni rinitis, kronična opstruktivna plućna bolest (COPD), reumatoidni artritis, kronične upalne bolesti crijeva (kronova bolest i ulcerativni kolitis), glomerulonefritis, psorijaza, osip, akutni i kronični cistitis; degenerativni poremećaji karakterizirani fibrozom kao što je hepatička ciroza, glomerulopatije i plućna fibroza, arteroskleroza, a zahvaljujući njihovoj analgetskoj aktivnosti u tretmanu akutne i kronične boli, primjerice opeklina, glavobolje, ugriza insekta, kronične boli kod pacijenata s karcinomom; kod poremećaja kardiovaskularnog aparata kao što je septički, alergijski i postraumatski šok i hepatička ciroza od hepatorenalnog sindroma; kao antikancerogena i antiangiogenetska sredstva, u tretmanu hipotenzije i alopecije.
The pharmaceutically acceptable liquid composition of claim 4, wherein the agent is L-cysteine, N-acetylcysteine (NAC), gluthatione (GSH), Na2-EDTA, Na2-EDTA-Ca, sodium bisulfite, or combinations thereof. 
Farmaceutski prihvatljiv tekući sastav iz zahtjeva 4, naznačeno time da je agent L-cistein, N-acetilcistein (NAC), glutation (GSH), Na,-EDTA, Na;-EDTA-Ca, natrijev bisulfit, ili kombinacije istih.
The pharmaceutical compositions for the use according to claim 11 and 12 wherein said cancer is prostate cancer. The pharmaceutical compositions for the use according to claim 11 and 12, wherein said urological disorders are selected from the group consisting of: painful bladder syndrome/interstitial cystitis, detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, lower urinary tract disorders and lower urinary tract symptoms. 
Tvari za uporabu u skladu s patentnim zahtjevom 7, pri čemu su navedeni poremećaj i/ili bolesti odabrani između kronične boli, neuropatske boli uključujući hladnu alodiniju i dijabetičku neuropatske boli, postoperativne boli, osteoartritičke boli, boli kod reumatoidnog artritisa, boli kod karcinoma, neuralgije, fibromijalgije, neuropatija, algezije, ozljede živca, migrena, glavobolja, svrbeži, sindroma iritabilnog crijeva i respiratornih bolesti, sindroma mjehura, intersticijskog cistitisa, pretjerane aktivnosti detruzora (preaktivnog mjehura), urinarne inkontinencije, neurogene pretjerane aktivnosti detruzora (hiperrefleksije detruzora), idiopatske pretjerane aktivnosti detruzora (nestabilnosti detruzora), benigne hiperplazije prostate, poremećaja donjih mokraćnih puteva i simptoma donjih mokraćnih puteva, tjeskobe i depresije
In some embodiments the composition comprises a therapeutically effective amount of insulin, an effervescent excipient component; and a bile salt. 
Oralni transmukozni pripravak naznačen time da sadrži: a) terapeutski učinkovitu količinu biološki aktivnog polipeptida; b) komponentu šumeće pomoćne tvari; i
Ther. Patents (2004) 14(5):703-732. These include cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. 
Spoj za uporabu u skladu s patentnim zahtjevom 11, naznačen time, da je navedena bolest ili poremećaj odabran između sljedećih: karcinom, poremećaji imunosnog sustava, kardiovaskularne bolesti, virusne infekcije, upale, poremećaji metabolizma/endokrinih funkcija i neurološki poremećaji.
The three ether layers were combined, washed with 1N HCI (2 x 100 ml.), washed with water (2 x 200 ml.), dried (MgS04), treated with activated carbon, filtered, and evaporated under vacuum to yield a solid, which was then crystallized from 200 ml., of hot hexane (36 g., 62% yield, m.p. 
Tri eterska sloja se spoje, isperu se sa IN HCI (2 x 200 ml.), isperu se sa vodom (2 x 200 ml.), suši se (MgSO:), tretira se sa aktiviranim ugljenom, filtrira, i ispari u vakuumu tako da se dobiva kruta supstancija, koja se kristalizira iz 200 ml. vrućeg heksana (36 g., 62% prinos, t.t. 107-108*C).
The method of claim 1, wherein the therapeutic monoclonal antibody is rituximab, trastuzumab, cetuximab, or panitumumab. 
Terapijsko monoklonsko protutijelo i kemijski spoj iz formule I za uporabu u skladu s patentnim zahtjevom 1, pri čemu je terapijsko monoklonsko protutijelo rituksimab, trastuzumab, cetuksimab, ili panitumumab.
K Use of a VZV antigen or immunogenic derivative therof in the preparation of an immunogenic composition for preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia, wherein the VZV antigen is used in combination with a live attenuated VZV strain or whole inactivated VZV strain 
VZV antigen gE, skraćen kako bi se uklonilo C-terminalno sidrišno područje, u kombinaciji s adjuvansom koji sadrži 3D-MPL, QS21 i liposomima koji sadrže kolesterol, naznačen time što je namijenjen upotrebi kao medikament za istodobnu ili uzastopnu primjenu uz živi oslabljeni VZV radi sprječavanja ili smanjivanja težine herpes zostera i/ili postherpetične neuralgije kod osoba koje su u opasnosti od takvih bolesti.
a decoder which is configured for performing prediction using at least one prediction unit included in the coding unit to generate a predictor, and reconstructing the coding unit using the residuals and the predictor, 
određivanje barem jedne jedinice predviđanja koja je razdvojena iz jedinice kodiranja koristeći informacije o jedinici predviđanja, pri čemu je informacija o jedinici predviđanja raščlanjena iz toka bitova;
Coupling device according to claim 3, wherein each hinge (36) is located between the proximal end and the distal end of the corresponding latch, such that said latch can pivot in a see-saw mode from its fixing position to its idle position by applying onto its distal end a force normal to both the hinge axle and the longitudinal axis, X1, and in the direction of the latter. 
Uređaj za spajanje u skladu s patentnim zahtjevom 3, naznačen time, da je svaki zglob (36) smješten između proksimalnog kraja 1 distalnog kraja odgovarajućeg zasuna, tako da se navedeni zasun može zakretati poput njihala od svog položaja pričvršćivanja do položaja praznog hoda primjenom sile na njegov distalni kraj, koja je okomita i na osovinu zgloba i na uzdužnu os XI, te u smjeru potonje.
In any additional process steps, carried out as desired, functional groups of the starting compounds which should not take part in the reaction may be present in unprotected form or may be protected, e.g., by one or more of the protecting groups mentioned below. 
U bilo kojem dodatnom stupnju postupka, koji se želi provesti, funkcionalne skupine polaznih spojeva koje ne smiju sudjelovati u reakciji mogu biti prisutne u nezaštićenom obliku ili se mogu zaštititi, npr. s jednom ili više dolje spomenutih zaštitnih skupina.
From the EEG spectral analysis performed before treatment, the study subjects could be stratified as microvolted (66%) and normo or grandvolted (33%). 
Iz EEG spektralne analize koja je obavljena prije tretmana, subjekti iz ove studije mogu se razvrstati u slojeve kao mikrovoltni (66%) i normo ili grandvoltni (33%).
The method of claim 6, wherein a number of encoded subsets is determined using a last non-zero coefficient position and the selected scan pattern. 
Postupak prema Zahtjevu 6, gdje se broj kodiranih podskupova određuje korištenjem posljednje pozicije koeficijenta različitog od nule odabranog obrasca skeniranja.
The process according to claim 1, wherein the partially purified aqueous stream leaving the bottom of the column is sent to a well in contact with the impeller of a pump suitably immersed and placed in a flooded suction position, to exert the necessary pressure on the water at the inlet of the subsequent unit working under pressure. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se djelomično očišćena vodna struja koja napušta dno stupca šalje u bunar koji je povezan s rotorom pumpe, koja pumpa je na odgovarajući način uronjena i smještena u položaj za isisavanje i to na takav način da je preplavljena, kako bi se stvorio potreban tlak na vodu koja je na ulazu sljedeće radne jedinice koja je u pogonu pod tlakom.
converting said acid addition salt of oxycodone to an oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone. 
Postupak prema zahtjevu 1, naznačen time da rezultantni sastav oksikodon hidroklorida sadrži 14-hidroksikodeinon u količini manjoj od 15 ppm.
A 7-(Morpholinyl)-2-(N-piperazinyl)methyl thieno[2,3-c]pyridine compound of Formula-I or a pharmaceutically acceptable salt thereof, 
Spoj 7-(morfolinil)-2-(N-piperazinil) metil tieno[2, 3-c]piridina formule I ili njegova farmaceutski prihvatljiva sol, naznačeno time, što:
Apparatus comprising a system for performing an industrial process (9) and a system for providing high microbiological quality cooling water to said system for performing an industrial process, where the system for performing an industriel process comprises an industrial plant, the apparatus comprising: 
Metoda za omogućavanje rashladne vode visoke mikrobiološke kvalitete za industrijske postupke, pri čemu industrijski postupak obuhvaća industrijsko postrojenje, metoda obuhvaća:
is H, or a substituted or unsubstituted C1-8 alkyl; and 
je supstituiran ili nesupstituiran cikloalkil; i R3 je H ili supstituirano ili nesupstituirani C1-8 alkil;
The process according to any one of claims 1 to 8, characterized in that said salt of a C5―C28 fatty acid is a salt of a fatty acid having an iodine number of less than 5 g I2/100 g of fatty acid salt. 
Postupak prema bilo kojem zahtjevu od 1 do 8, naznačen time da navedena sol Cs - Cxg masne kiseline je sol masne kiseline koja ima jodni broj od manje od 5 g 1/100 g soli masne kiseline.
G is any of the following Ga to Ge: 
M? je bilo koji od sljedećih M" do M"':
A compound comprising a residue of an opioid agonist covalently attached to a water-soluble, non-peptidic oligomer. 
Spoj opioidnog agonista koji sadrži ostatak opioidnog agonista kovalentno vezan na u vodi topiv, ne-peptidni oligomer, te spoj ima formulu: [image] naznačen time da: